Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 687

Results For "CE"

9359 News Found

hubergroup India expands its support for rural healthcare
Healthcare | March 24, 2023

hubergroup India expands its support for rural healthcare

hubergroup’s two newly added medical vans are dedicated to dental and eye care


PM chairs high-level meeting to asses situation of Covid-19 & Influenza
Policy | March 23, 2023

PM chairs high-level meeting to asses situation of Covid-19 & Influenza

PM emphasises the need to enhance lab surveillance & testing of all Severe Acute Respiratory Illness (SARI) cases & ramp up genome sequencing


PM to address One World TB Summit tomorrow
News | March 23, 2023

PM to address One World TB Summit tomorrow

PM to launch TB-Mukt Panchayat initiative; official pan-India rollout of a shorter TB Preventive Treatment and Family-centric care model for TB


Emmes acquires Essex Management
News | March 23, 2023

Emmes acquires Essex Management

Essex enriches and complements Emmes’ services


FedEx Express to showcase healthcare solutions at Indian Biologics Festival 2023
Supply Chain | March 23, 2023

FedEx Express to showcase healthcare solutions at Indian Biologics Festival 2023

FedEx will be displaying a wide-range of effective healthcare packaging and specialized tracking technology


Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study
Clinical Trials | March 23, 2023

Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study

The data from this study show that MM-II has the potential to provide durable pain relief for our patients


Granules Consumer Health concludes FDA audit with zero observations
Drug Approval | March 22, 2023

Granules Consumer Health concludes FDA audit with zero observations

The audit is a pre-approval inspection for three products filed from the facility


Zydus granted Orphan Drug Designation by USFDA for ZYIL1
Drug Approval | March 22, 2023

Zydus granted Orphan Drug Designation by USFDA for ZYIL1

ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates


Serum Institute of India likely front-runner to win supply of HPV vaccines for UIP, says GlobalData
News | March 21, 2023

Serum Institute of India likely front-runner to win supply of HPV vaccines for UIP, says GlobalData

The Indian government will float a global tender in April 2023 to procure HPV vaccines.


Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing
Clinical Trials | March 21, 2023

Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing

All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking